These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

934 related items for PubMed ID: 16689923

  • 1. Protein-misfolding diseases and chaperone-based therapeutic approaches.
    Chaudhuri TK, Paul S.
    FEBS J; 2006 Apr; 273(7):1331-49. PubMed ID: 16689923
    [Abstract] [Full Text] [Related]

  • 2. Protein misfolding in neurodegenerative diseases.
    Agorogiannis EI, Agorogiannis GI, Papadimitriou A, Hadjigeorgiou GM.
    Neuropathol Appl Neurobiol; 2004 Jun; 30(3):215-24. PubMed ID: 15175075
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. How a cell deals with abnormal proteins. Pathogenetic mechanisms in protein aggregation diseases.
    Aigelsreiter A, Janig E, Stumptner C, Fuchsbichler A, Zatloukal K, Denk H.
    Pathobiology; 2007 Jun; 74(3):145-58. PubMed ID: 17643060
    [Abstract] [Full Text] [Related]

  • 6. Mechanisms of disease II: cellular protein quality control.
    Outeiro TF, Tetzlaff J.
    Semin Pediatr Neurol; 2007 Mar; 14(1):15-25. PubMed ID: 17331880
    [Abstract] [Full Text] [Related]

  • 7. Proteopathy: the next therapeutic frontier?
    Walker LC, LeVine H.
    Curr Opin Investig Drugs; 2002 May; 3(5):782-7. PubMed ID: 12090553
    [Abstract] [Full Text] [Related]

  • 8. The role of molecular chaperones in human misfolding diseases.
    Broadley SA, Hartl FU.
    FEBS Lett; 2009 Aug 20; 583(16):2647-53. PubMed ID: 19393652
    [Abstract] [Full Text] [Related]

  • 9. Developing therapeutics for the diseases of protein misfolding.
    May BC, Govaerts C, Cohen FE.
    Neurology; 2006 Jan 24; 66(2 Suppl 1):S118-22. PubMed ID: 16432139
    [Abstract] [Full Text] [Related]

  • 10. Therapeutic approaches to protein-misfolding diseases.
    Cohen FE, Kelly JW.
    Nature; 2003 Dec 18; 426(6968):905-9. PubMed ID: 14685252
    [Abstract] [Full Text] [Related]

  • 11. [Neurodegenerative conformational disease and its molecular bases].
    Li WW, Cai DF, Ren HM.
    Sheng Li Ke Xue Jin Zhan; 2006 Apr 18; 37(2):97-102. PubMed ID: 16850610
    [Abstract] [Full Text] [Related]

  • 12. Structure and function of the molecular chaperone Hsp104 from yeast.
    Grimminger-Marquardt V, Lashuel HA.
    Biopolymers; 2010 Mar 18; 93(3):252-76. PubMed ID: 19768774
    [Abstract] [Full Text] [Related]

  • 13. Approaches to the isolation and characterization of molecular chaperones.
    Nicoll WS, Boshoff A, Ludewig MH, Hennessy F, Jung M, Blatch GL.
    Protein Expr Purif; 2006 Mar 18; 46(1):1-15. PubMed ID: 16199180
    [Abstract] [Full Text] [Related]

  • 14. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease.
    Glabe CG.
    Neurobiol Aging; 2006 Apr 18; 27(4):570-5. PubMed ID: 16481071
    [Abstract] [Full Text] [Related]

  • 15. Small heat-shock proteins and clusterin: intra- and extracellular molecular chaperones with a common mechanism of action and function?
    Carver JA, Rekas A, Thorn DC, Wilson MR.
    IUBMB Life; 2003 Dec 18; 55(12):661-8. PubMed ID: 14769002
    [Abstract] [Full Text] [Related]

  • 16. Defective protein folding and aggregation as the basis of neurodegenerative diseases: the darker aspect of proteins.
    Naeem A, Fazili NA.
    Cell Biochem Biophys; 2011 Nov 18; 61(2):237-50. PubMed ID: 21573992
    [Abstract] [Full Text] [Related]

  • 17. Amino acid sequence determinants and molecular chaperones in amyloid fibril formation.
    Nerelius C, Fitzen M, Johansson J.
    Biochem Biophys Res Commun; 2010 May 21; 396(1):2-6. PubMed ID: 20494101
    [Abstract] [Full Text] [Related]

  • 18. Modeling and analysis of prion dynamics in the presence of a chaperone.
    Kumar R, Murali P.
    Math Biosci; 2008 May 21; 213(1):50-5. PubMed ID: 18362035
    [Abstract] [Full Text] [Related]

  • 19. Contribution of glutamatergic signaling to nitrosative stress-induced protein misfolding in normal brain aging and neurodegenerative diseases.
    Nakamura T, Gu Z, Lipton SA.
    Aging Cell; 2007 Jun 21; 6(3):351-9. PubMed ID: 17388798
    [Abstract] [Full Text] [Related]

  • 20. S-Nitrosylation and uncompetitive/fast off-rate (UFO) drug therapy in neurodegenerative disorders of protein misfolding.
    Nakamura T, Lipton SA.
    Cell Death Differ; 2007 Jul 21; 14(7):1305-14. PubMed ID: 17431424
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.